SUMOylation Regulator-Related Molecules Can Be Used as Prognostic Biomarkers for Glioblastoma

Xiaozhi Li,Yutong Meng

doi:10.3389/fcell.2021.658856

Abstract

IntroductionSUMOylation is one of the post-translational modifications. The relationship between the expression of SUMOylation regulators and the prognosis of glioblastoma is not quite clear.Materials and MethodsThe single nucleotide variant data, the transcriptome data, and survival information were acquired from The Cancer Genome Atlas, Gene Expression Omnibus, and cBioportal database. Wilcoxon test was used to analyze differentially expressed genes between glioblastoma and normal brain tissues. Gene set enrichment analysis was conducted to find the possible functions. One risk scoring model was built by the least absolute shrinkage and selection operator Cox regression. Kaplain–Meier survival curves and receiver operating characteristic curves were applied to evaluate the effectiveness of the model in predicting the prognosis of glioblastoma.ResultsSingle-nucleotide variant mutations were found in SENP7, SENP3, SENP5, PIAS3, RANBP2, USPL1, SENP1, PIAS2, SENP2, and PIAS1. Moreover, UBE2I, UBA2, PIAS3, and SENP1 were highly expressed in glioblastoma, whereas PIAS1, RANBP2, SENP5, and SENP2 were downregulated in glioblastoma. Functional enrichment analysis showed that the SUMOylation regulators of glioblastoma might involve cell cycle, DNA replication, and other functions. A prognostic model of glioblastoma was constructed based on SUMOylation regulator-related molecules (ATF7IP, CCNB1IP1, and LBH). Kaplain–Meier survival curves and receiver operating characteristic curves showed that the model had a strong ability to predict the overall survival of glioblastoma.ConclusionThis study analyzed the expression of 15 SUMOylation regulators in glioblastoma. The risk assessment model was constructed based on the SUMOylation regulator-related genes, which had a strong predictive ability for the overall survival of patients with glioblastoma. It might provide targets for the study of the relationship between SUMOylation and glioblastoma.

Highlights

SUMOylation is one of the post-translational modifications
As can be seen from the figure, UBE2I, UBA2, PIAS3, and SENP1 were upregulated in glioblastoma, whereas PIAS1, RANBP2, SENP5, and SENP2 were downregulated in glioblastoma
As one of the important results of this study, we found that UBE2I, UBA2, PIAS3, SENP1, PIAS1, RANBP2, SENP5, and SENP2 were differentially expressed in glioblastoma

Summary

Introduction

SUMOylation is one of the post-translational modifications. The relationship between the expression of SUMOylation regulators and the prognosis of glioblastoma is not quite clear. Glioblastoma is the most malignant intracranial tumor originating from glial cells. Common treatments for glioblastoma include microsurgery, the use of chemotherapy drugs, such as temozolomide, and radiotherapy. The prognosis of patients with glioblastoma is still very poor. Studies have shown that the 5-year survival rate is only approximately 5%. Due to the high cost of treatment of glioblastoma and poor treatment effect, it has always been one of the difficulties in tumor treatment (Cloughesy et al, 2020; Faria et al, 2020; Reardon et al, 2020). It is of great importance to find effective molecular targets and improve the prognosis of glioblastoma

Objectives

Methods

Results

Discussion

Conclusion